Gemcitabine versus Modified Gemcitabine: a review of several promising chemical modifications.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Molecular Pharmaceutics

• Publication date

  2013-02-04

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/mp300370tPMID 22978251
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Squalenoylation: a generic platform for nanoparticular drug delivery.

  2012cited by this paper
• EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activity.

  2012cited by this paper
• Magnetic nanocarriers of doxorubicin coated with poly(ethylene glycol) and folic acid: relation between coating structure, surface properties, colloidal stability, and cancer cell targeting.

  2012cited by this paper
• EGFR-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma.

  2012cited by this paper
• Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1.

  2012cited by this paper
• In vitro and in vivo assessment of targeting lipid-based nanoparticles to the epidermal growth factor-receptor (EGFR) using a novel Heptameric ZEGFR domain.

  2012cited by this paper
• PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery.

  2012cited by this paper
• State of the art in PEGylation: the great versatility achieved after forty years of research.

  2012cited by this paper
• Sensitizing of gemcitabine-resistant human leukemia cells by stearoyl gemcitabine nanoparticles .

  2011cited by this paper
• Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.

  2011cited by this paper
• Magnetic functionalised carbon nanotubes as drug vehicles for cancer lymph node metastasis treatment.

  2011cited by this paper
• INX-08189, a Phosphoramidate Prodrug of 6-O-Methyl-2′-C-Methyl Guanosine, Is a Potent Inhibitor of Hepatitis C Virus Replication with Excellent Pharmacokinetic and Pharmacodynamic Properties

  2011cited by this paper
• Effect of its deaminated metabolite, 2',2'-difluorodeoxyuridine, on the transport and toxicity of gemcitabine in HeLa cells.

  2011cited by this paper
• Multimeric, Multifunctional Derivatives of Poly(ethylene glycol)

  2011cited by this paper
• Covalent conjugation of poly(ethylene glycol) to proteins and peptides: strategies and methods.

  2011cited by this paper
• Deoxyuridine analog nucleotides in deoxycytidine analog treatment: secondary active metabolites?

  2011cited by this paper
• The cytostatic activity of NUC-3073, a phosphoramidate prodrug of 5-fluoro-2'-deoxyuridine, is independent of activation by thymidine kinase and insensitive to degradation by phosphorolytic enzymes.

  2011cited by this paper
• Gemcitabine-loaded chitosan microspheres. Characterization and biological in vitro evaluation

  2011cited by this paper
• Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors

  2011cited by this paper
• In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles.

  2011cited by this paper
• Deficiency of Cardiolipin Synthase Causes Abnormal Mitochondrial Function and Morphology in Germ Cells of Caenorhabditis elegans*

  2011cited by this paper
• Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC).

  2011cited by this paper
• EGFR-Targeted Hybrid Plasmonic Magnetic Nanoparticles Synergistically Induce Autophagy and Apoptosis in Non-Small Cell Lung Cancer Cells

  2011cited by this paper
• EGFR targeted PLGA nanoparticles using gemcitabine for treatment of pancreatic cancer.

  2011cited by this paper
• Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy.

  2011cited by this paper
• A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy

  2011cited by this paper
• Gemcitabine-loaded innovative nanocarriers vs GEMZAR: Biodistribution, pharmacokinetic features and in vivo antitumor activity

  2011cited by this paper
• Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics.

  2011cited by this paper
• Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126

  2011cited by this paper
• Novel nanoassemblies composed of squalenoyl-paclitaxel derivatives: synthesis, characterization, and biological evaluation.

  2010cited by this paper
• The Activity of the Lipophilic Nucleoside Derivatives Elacytarabine and CP-4126 in a Panel of Tumor Cell Lines Resistant to Nucleoside Analogues

  2010cited by this paper
• Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models

  2010cited by this paper
• Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs.

  2010cited by this paper
• Liposomal squalenoyl-gemcitabine: formulation, characterization and anticancer activity evaluation.

  2010cited by this paper
• Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathway.

  2010cited by this paper
• Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells.

  2010cited by this paper
• Folic acid-conjugated chitosan nanoparticles enhanced protoporphyrin IX accumulation in colorectal cancer cells.

  2010cited by this paper
• Endocytosis of PEGylated Agents Enhances Cancer Imaging and Anticancer Efficacy

  2010cited by this paper
• HuR Status is a Powerful Marker for Prognosis and Response to Gemcitabine-Based Chemotherapy for Resected Pancreatic Ductal Adenocarcinoma Patients

  2010cited by this paper
• Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.

  2010cited by this paper
• Modulation of the Ribonucleotide Reductase-Antimetabolite Drug Interaction in Cancer Cell Lines

  2010cited by this paper
• Advanced pancreatic carcinoma: current treatment and future challenges

  2010cited by this paper
• Long circulation and cytotoxicity of PEGylated gemcitabine and its potential for the treatment of pancreatic cancer.

  2010cited by this paper
• Phosphoramidates of 2′-β-d-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism

  2010cited by this paper
• Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus.

  2010cited by this paper
• Contribution of Thymidylate Synthase to Gemcitabine Therapy for Advanced Pancreatic Cancer

  2010cited by this paper
• Functional Folate Receptor Alpha Is Elevated in the Blood of Ovarian Cancer Patients

  2009cited by this paper
• Innovations and opportunities to improve conventional (deoxy)nucleoside and fluoropyrimidine analogs in cancer.

  2009cited by this paper
• CP‐4055 and CP‐4126 are active in ara‐C and gemcitabine‐resistant lymphoma cell lines

  2009cited by this paper
• Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma

  2009cited by this paper
• Anti-metastatic effects of liposomal gemcitabine in a human orthotopic LNCaP prostate cancer xenograft model

  2009cited by this paper
• Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine.

  2009cited by this paper
• Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.

  2009cited by this paper
• Intravenous administration of CP-4055 (ELACYT™) in patients with solid tumours. A phase I study

  2009cited by this paper
• The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.

  2009cited by this paper
• Cell cycle effects of fatty acid derivatives of cytarabine, CP-4055, and of gemcitabine, CP-4126, as basis for the interaction with oxaliplatin and docetaxel.

  2009cited by this paper
• Biological and Pharmacological Activities of Squalene and Related Compounds: Potential Uses in Cosmetic Dermatology

  2009cited by this paper
• PEG conjugates in clinical development or use as anticancer agents: an overview.

  2009cited by this paper
• The Role of Human Nucleoside Transporters in Uptake of 3′-Deoxy-3′-fluorothymidine

  2008cited by this paper
• Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid.

  2008cited by this paper
• Polyethylene glycol (PEG) as a key component of long-circulating delivery systems for therapy and imaging

  2008cited by this paper
• Expression Status of Folate Receptor α Is Significantly Correlated with Prognosis in Non-Small-Cell Lung Cancers

  2008cited by this paper
• Nano-sized assemblies of a PEG-docetaxel conjugate as a formulation strategy for docetaxel.

  2008cited by this paper
• Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo.

  2008cited by this paper
• Endocytic mechanisms for targeted drug delivery.

  2007cited by this paper
• Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells.

  2007cited by this paper
• Synthesis and biological activity of a gemcitabine phosphoramidate prodrug.

  2007cited by this paper
• Antitumor activity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs.

  2007cited by this paper
• A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types.

  2007cited by this paper
• Folate receptor overexpression is associated with poor outcome in breast cancer

  2007cited by this paper
• Cathepsin L increases invasion and migration of B16 melanoma

  2007cited by this paper
• Encapsulation of gemcitabine lipophilic derivatives into polycyanoacrylate nanospheres and nanocapsules.

  2007cited by this paper
• Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.

  2006cited by this paper
• Immunohistochemical and Genetic Evaluation of Deoxycytidine Kinase in Pancreatic Cancer: Relationship to Molecular Mechanisms of Gemcitabine Resistance and Survival

  2006cited by this paper
• Squalenoyl nanomedicines as potential therapeutics.

  2006cited by this paper
• In-vitro and in-vivo anti-cancer activity of a novel gemcitabine–cardiolipin conjugate

  2006cited by this paper
• Gemcitabine and carboplatin in second-line ovarian cancer.

  2005cited by this paper
• Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity.

  2005cited by this paper
• Synthesis and biological evaluation of gemcitabine-lipid conjugate (NEO6002).

  2005cited by this paper
• Safety of Pulmonary Administration of Gemcitabine in Rats

  2005cited by this paper
• Gemcitabine plus paclitaxel in breast cancer.

  2005cited by this paper
• Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug.

  2004cited by this paper
• Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines.

  2004cited by this paper
• Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs.

  2004cited by this paper
• PEG-Ara-C conjugates for controlled release.

  2004cited by this paper
• Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors.

  2004cited by this paper
• RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine

  2004cited by this paper
• Characterization of a Gemcitabine-Resistant Murine Leukemic Cell Line

  2004cited by this paper
• A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration.

  2003cited by this paper
• Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer.

  2003cited by this paper
• Cathepsin B and its role(s) in cancer progression.

  2003cited by this paper
• From Conventional to Stealth Liposomes a new Frontier in Cancer Chemotherapy

  2003cited by this paper
• Effect of pegylation on pharmaceuticals

  2003cited by this paper
• Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates.

  2003cited by this paper
• The role of membrane transporters in cellular resistance to anticancer nucleoside drugs.

  2002cited by this paper
• Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).

  2002cited by this paper
• Intracellular delivery of nanometric DNA particles via the folate receptor.

  2002cited by this paper
• Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.

  2001cited by this paper
• EGFR and cancer prognosis.

  2001cited by this paper
• Synthesis and biological studies of novel nucleoside phosphoramidate prodrugs.

  2001cited by this paper

• Biodegradable polymersomes encapsulating copper peroxide and gemcitabine for targeted chemoimmunotherapy.

  2026cites this paper
• Enhancement of gemcitabine toxicity and specificity through PI3K/Akt/Nrf2 pathway inhibition in pancreatic cancer.

  2026cites this paper
• Carboxymethyl-β-1,3-D-glucan (CMG)-gemcitabine conjugate improves the anticancer efficacy and alleviate the toxicity of gemcitabine (GEM).

  2025cites this paper
• The critical role of NLRP3 in drug resistance of cancers: Focus on the molecular mechanisms and possible therapeutics.

  2025cites this paper
• Rational Design of Metal–Organic Frameworks for Pancreatic Cancer Therapy: from Machine Learning Screening to In Vivo Efficacy

  2025cites this paper
• Friends Fight the Foes: Synergistic Low‐Temperature Photothermal/Chemo/Gas Therapy for Conquering Cancer Cells

  2025cites this paper
• Graph theoretic and machine learning approaches in molecular property prediction of bladder cancer therapeutics

  2025cites this paper
• A novel gemcitabine analog as a potential anticancer agent: synthesis and in-vitro evaluation against pancreatic cancer.

  2025cites this paper
• Prospects for the creation of a liposomal gemcitabine delivery system

  2025cites this paper
• Dual pH-Responsive Calcium Phosphate Nanoparticles Conjugated with Folate by CuAAC Click Chemistry for Targeted Gemcitabine Delivery to Cancer Cells

  2025cites this paper
• Hyaluronic acid-conjugated lipid nanocarriers in advancing cancer therapy: A review.

  2025cites this paper
• Enhanced anticancer activity of novel pyrimidine nucleoside analog in pancreatic cancer.

  2025cites this paper
• Some stereoisomers and tautomers of gemcitabine – A DFT treatment

  2025cites this paper
• Self-assembled polyelectrolyte drug conjugates with minimal hemolytic activity for precision oncology

  2025cites this paper
• Colon cancer-cell-specific drug delivery by gemcitabine conjugated with peptide chain targeting ENO1.

  2025cites this paper
• Development of heterocyclic-based anticancer agents: A comprehensive review

  2025cites this paper
• Rice Bran Extract-Assisted Synthesis of PMO/ZnO Nanocomposites for Enhanced Gemcitabine Loading and Anticancer Efficacy

  2025cites this paper
• Pectin based Stimuli Responsive Nanovesicles: A Promising Strategy for Sustained Release, and Augmenting Bioavailability of Gemcitabine

  2025cites this paper
• Construction of a smart dual-responsive targeted drug nanocarrier for imaging and treatment of breast cancer cells.

  2025cites this paper
• Influence of Water/Ethanol Mixing Ratio on Gemcitabine Binding to Cucurbit-7-uril Based on Molecular Dynamics Simulations and Three-Dimensional Reference Interaction Site Model

  2025cites this paper
• Gemcitabine-loaded poly (lactide-co-glycolide) – poly (ethylene glycol) gold nanoparticles: Evaluating the effect of fabricating methods on physicochemical characteristics, in vitro drug release and cytotoxicity

  2025cites this paper
• Design, Synthesis, and Activity Evaluation of Novel Nucleosides as ADAR1 Inhibitor for the Treatment of Prostate Cancer.

  2025cites this paper
• Ultrasonic activation of polymer-drug conjugates for targeted and combinational pancreatic cancer therapy.

  2025cites this paper
• Polymeric Nanoparticles Engineered for Optimal Drug Delivery Using Atomistic Computational Simulation

  2024cites this paper
• Complications and comorbidities associated with antineoplastic chemotherapy: Rethinking drug design and delivery for anticancer therapy

  2024cites this paper
• Revolutionizing Cancer Treatment: ROS-Induced Apoptosis via Nanoformulated Alkaloids

  2024cites this paper
• Targeting Intracranial Tumours with a Combination of RNA and Chemotherapy

  2024cites this paper
• A cathepsin B-sensitive gemcitabine prodrug for enhanced pancreatic cancer therapy.

  2024cites this paper
• A fluorescent gemcitabine prodrug that follows a nucleoside transporter-independent internalization and bears enhanced therapeutic efficacy with respect to gemcitabine.

  2024cites this paper
• Electrochemical sensor based on reduced graphene oxide paste electrode for detection of gemcitabine as a chemotherapy drug in breast cancer

  2024cites this paper
• Tumor Microenvironment Modulates Invadopodia Activity of Non-Selected and Acid-Selected Pancreatic Cancer Cells and Its Sensitivity to Gemcitabine and C18-Gemcitabine

  2024cites this paper
• Drugs That Mimic Hypoxia Selectively Target EBV-Positive Gastric Cancer Cells

  2023cites this paper
• Electronic spectroscopy of gemcitabine and derivatives for possible dual-action photodynamic therapy applications.

  2023cites this paper
• Targeting self-enhanced ROS-responsive artesunatum prodrug nanoassembly potentiates gemcitabine activity by down-regulating CDA expression in cervical cancer

  2023cites this paper
• Synthesis and anticancer evaluation of acetylated-lysine conjugated gemcitabine prodrugs.

  2023cites this paper
• Cytotoxicity against A549 Human Lung Cancer Cell Line via the Mitochondrial Membrane Potential and Nuclear Condensation Effects of Nepeta paulsenii Briq., a Perennial Herb

  2023cites this paper
• Research Progress in Drug Resistance and Structural Modification of Gemcitabine

  2023cites this paper
• Understanding cellular senescence: pathways involved, therapeutics and longevity aiding

  2023cites this paper
• Engineered Hierarchical Microdevices Enable Pre‐Programmed Controlled Release for Postsurgical and Unresectable Cancer Treatment

  2023cites this paper
• Biodegradable nanocarrier of gemcitabine and tocopherol succinate synergistically ameliorates anti-proliferative response in MIA PaCa-2 cells.

  2023cites this paper
• Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer

  2023cites this paper
• A novel synthesized prodrug of gemcitabine based on oxygen-free radical sensitivity inhibited the growth of lung cancer cells

  2023cites this paper
• Effectiveness of anti-erythropoietin producing Hepatocellular receptor Type-A2 antibody in pancreatic cancer treatment

  2023cites this paper
• Glioblastoma-targeted, local and sustained drug delivery system based on an unconventional lipid nanocapsule hydrogel.

  2023cites this paper
• Small anticancer drug release by light: Photochemical internalization of porphyrin-β-cyclodextrin nanoparticles.

  2023cites this paper
• Design of the New Closo-Dodecarborate-Containing Gemcitabine Analogue for the Albumin-Based Theranostics Composition

  2023cites this paper
• Intratumoral injection therapies for locally advanced pancreatic cancer: systematic review

  2023influential citation
• Modulating gut microbiota using nanotechnology to increase anticancer efficacy of the treatments

  2023cites this paper
• Fine-tuning the sequential drug release of nano-formulated mutual prodrugs dictates the combination effects

  2023cites this paper
• Application of ProTide Technology to Gemcitabine: A successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development.

  2022cites this paper
• Efficacy of Eribulin Plus Gemcitabine Combination in L-Sarcomas

  2022cites this paper
• WRQ-2, a gemcitabine prodrug, reverses gemcitabine resistance caused by hENT1 inhibition.

  2022cites this paper
• LogP of N-acyl-gemcitabine and lectin-corona emerge as key parameters in nanoparticulate intravesical cancer therapy.

  2022cites this paper
• Exosome-Mediated Response to Cancer Therapy: Modulation of Epigenetic Machinery

  2022cites this paper
• Amphiphilic Dendritic Nanomicelle-Mediated Delivery of Gemcitabine for Enhancing the Specificity and Effectiveness

  2022cites this paper
• Degradable polyprodrugs: design and therapeutic efficiency.

  2022cites this paper
• Binding Sites of Anticancer Drugs on Human Serum Albumin (HSA): A Review.

  2022cites this paper
• Trimethoxy trityl groups as a potent substituent for anti-cancer cytidine analog prodrugs.

  2022cites this paper
• Broader and safer clinically-relevant activities of pentadecanoic acid compared to omega-3: Evaluation of an emerging essential fatty acid across twelve primary human cell-based disease systems

  2022cites this paper
• Wirelessly Activated Nanotherapeutics for In Vivo Programmable Photodynamic‐Chemotherapy of Orthotopic Bladder Cancer

  2022cites this paper
• Design, synthesis and antitumor activity study of a gemcitabine prodrug conjugated with a HDAC6 inhibitor.

  2022cites this paper
• Redox-responsive Self-assembled Polymeric Nanoprodrug for Delivery of Gemcitabine in B-cell Lymphoma Therapy.

  2022cites this paper
• Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics

  2022cites this paper
• Pharmacological Modulation of Apoptosis and Autophagy in the Treatment of Pancreatic Cancer.

  2022cites this paper
• Self-assembled coumarin- and 5-fluorouracil-PEG micelles as multifunctional drug delivery systems

  2022cites this paper
• Two Possible Strategies for Drug Modification of Gemcitabine and Future Contributions to Personalized Medicine

  2022influential citation
• Before in vivo studies: In vitro screening of sphingomyelin nanosystems using a relevant 3D multicellular pancreatic tumor spheroid model.

  2022cites this paper
• Development of Fluorophosphoramidate as a Biocompatibly Transformable Functional Group and its Application as a Phosphate Prodrug for Nucleoside Analogs

  2022cites this paper
• Gemcitabine Peptide-Based Conjugates and Their Application in Targeted Tumor Therapy

  2021cites this paper
• One-Step in-Situ Growth of MoS2@Lentinan as a Dual-Stimuli-Responsive Nanocarrier for Synergistic Chemo-Photothermal Therapy

  2021cites this paper
• Design, synthesis, and evaluation of liver-specific gemcitabine prodrugs for potential treatment of hepatitis C virus infection and hepatocellular carcinoma.

  2021cites this paper
• Therapeutic potential of thymoquinone in combination therapy against cancer and cancer stem cells

  2021cites this paper
• The evolution of nucleosidic analogues: self-assembly of prodrugs into nanoparticles for cancer drug delivery

  2021cites this paper
• Targeting nucleotide metabolism as the nexus of viral infections, cancer, and the immune response

  2021cites this paper
• A Tumor-Penetrating Nanomedicine Improves the Chemoimmunotherapy of Pancreatic Cancer.

  2021cites this paper
• A Diels-Alder polymer platform for thermally enhanced drug release toward efficient local cancer chemotherapy

  2021cites this paper
• Emerging pro-drug and nano-drug strategies for gemcitabine-based cancer therapy

  2021cites this paper
• CC Chemokine Receptor 2-Targeting Copper Nanoparticles for Positron Emission Tomography-Guided Delivery of Gemcitabine for Pancreatic Ductal Adenocarcinoma.

  2021cites this paper
• Synthesis and cytotoxicity evaluation of gemcitabine-tobacco mosaic virus conjugates

  2021cites this paper
• Tumor Microenvironment and Intracellular Signal-Activated Nanocomposites for Anticancer Drug Delivery

  2021cites this paper
• Synthesis and biological evaluation of pyrrolidine-functionalized nucleoside analogs

  2021cites this paper
• Recent Advances in Lipid-Based Nanosystems for Gemcitabine and Gemcitabine–Combination Therapy

  2021influential citation
• Ultrasound-Mediated Gemcitabine Delivery Reduces the Normal-Tissue Toxicity of Chemoradiation Therapy in a Muscle-Invasive Bladder Cancer Model

  2021cites this paper
• Structural Effects of Incorporation of 2´-Deoxy-2´2´-difluorodeoxycytidine (Gemcitabine) in A- and B-form Duplexes.

  2021cites this paper
• A gemcitabine-based conjugate with enhanced antitumor efficacy by suppressing HIF-1α expression under hypoxia.

  2021cites this paper
• Integrin-Mediated Targeted Cancer Therapy Using c(RGDyK)-Based Conjugates of Gemcitabine.

  2021cites this paper
• Self-assembly of prodrugs into nanoparticles: evolving nucleosidic analogues to the next paradigm shift in the field of anticancer drug delivery

  2021cites this paper
• Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels

  2020cites this paper
• Preparation of carbon quantum dots- quinic acid for drug delivery of gemcitabine to breast cancer cells

  2020cites this paper
• Synergistic effects of piperlongumine and gemcitabine against KRAS mutant lung cancer

  2020cites this paper
• Sustained release of lipophilic gemcitabine from an injectable polymeric hydrogel for synergistically enhancing tumor chemoradiotherapy

  2020cites this paper
• Gemcitabine-retinoid prodrug loaded nanoparticles display in vitro antitumor efficacy towards drug-resilient human PANC-1 pancreatic cancer cells.

  2020cites this paper
• Co-delivery of gemcitabine prodrug along with anti NF-κB siRNA by tri-layer micelles can increase cytotoxicity, uptake and accumulation of the system in the cancers.

  2020cites this paper
• Targeting Pancreatic Ductal Adenocarcinoma (PDAC).

  2020cites this paper
• Poly(anhydride-ester) gemcitabine: Synthesis and particle engineering of a high payload hydrolysable polymeric drug for cancer therapy.

  2020cites this paper
• Development of programmable gemcitabine-GnRH pro-drugs bearing linker controllable "click" oxime bond tethers and preclinical evaluation against prostate cancer.

  2020cites this paper
• Elimination of senescent cells by β-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice

  2020cites this paper
• Development of potent CPP6-gemcitabine conjugates against human prostate cancer cell line (PC-3).

  2020cites this paper
• Supramolecular Aggregation-Induced Emission Nanodots with Programmed Tumor Microenvironment Responsiveness for Image-Guided Orthotopic Pancreatic Cancer Therapy.

  2020cites this paper
• Drug repurposing of pyrimidine analogs as potent antiviral compounds against human enterovirus A71 infection with potential clinical applications

  2020cites this paper